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Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine
reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is
one of only three medications in this class available in the United States.
Aims: The objective of this article is to review the published evidence for the safety and
efficacy of desvenlafaxine, and to compare it to other antidepressants to delineate its role in
the treatment of depression.
Evidence review: At the recommended dose of 50 mg per day the rate of response and remission
was similar to other SNRIs, as was the adverse effect profile. The rate of discontinuation was
no greater than placebo, and a discontinuation syndrome was not observed at this dose. Higher
doses were not associated with greater efficacy, but they did lead to more side effects, and the
use of a taper prior to discontinuation. The most common side effects reported were insomnia,
somnolence, dizziness, and nausea. Some subjects experienced clinically significant blood
pressure elevation.
Place in therapy: Like duloxetine, desvenlafaxine inhibits the reuptake of both norepinephrine
and serotonin at the starting dose. Dual reuptake inhibitors have been shown to have small but
statistically significantly greater rates of response and remission compared to selective serotonin
reuptake inhibitors, and they have also shown early promise in the treatment of neuropathic
pain. Desvenlafaxine may prove to be a valuable treatment option by expanding the limited
number of available dual reuptake inhibitors.
Keywords: desvenlafaxine, depression, reuptake inhibitors, norepinephrine, serotonin
Core evidence outcomes summary for desvenlafaxine in depression
Outcome measure
Disease-oriented evidence
Significant reduction in depression
symptoms (HAMD17)
Discontinuation due to adverse events
in the 50 mg group was similar to
placebo
No serious symptoms associated with
discontinuation of 50 mg dose (DESS)
Reduction in various indices of chronic
pain (VAS-PI)
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Patient-oriented evidence
Reduction in disability indices (SDS)
Improvement in psychological
well-being indices (WHO-5)

Evidence

Implications/Comments

Substantial

Desvenlafaxine effectively treats
depression at 50–100 mg per day.
Desvenlafaxine 50–100 mg per day is safe
and well-tolerated.

Substantial

Clear
Moderate

Clear
Clear

Desvenlafaxine 50 mg can be
discontinued without a taper.
Desvenlafaxine may be useful in treating
chronic pain, however the clinical trials were
not designed to measure efficacy for pain.
Desvenlafaxine produced a significant
reduction in disability due to depression.
Desvenlafaxine significantly improved
psychological well-being.
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Scope, aims, and objectives
Desvenlafaxine (DVS) is the most recently approved
medication for the treatment of major depressive disorder.
DVS is chemically unrelated to tricyclic, tetracyclic, or other
available antidepressants (with the exception of venlafaxine),
and is classified as a dual-acting serotonin (5-HT) and
norepinephrine (NE) reuptake inhibitor (SNRI). Nonclinical
studies have demonstrated that it inhibits the neuronal uptake
of both 5-HT and NE and, to a lesser degree, dopamine.
It does not have any monoamine oxidase inhibitory activity,
and it shows virtually no affinity for rat brain muscarinic cholinergic, H1-histaminergic, or alpha-1 adrenergic receptors.
The objective of this article is to review the published
evidence for the safety and efficacy of DVS that led to its
approval by the US Food and Drug Administration (FDA).
Additionally, DVS is compared to other antidepressants
in order to delineate the advantages and disadvantages
of this drug, and its appropriate place in the treatment of
depression.

Methods
The English language medical literature was searched in
August 2008 using the following databases. Search terms
used were “desvenlafaxine OR DVS.” Nonhuman and
in vitro studies were excluded from the search. Results are
shown in Table 1.
• PubMed, http://www.ncbi.nlm.nih.gov/sites/entrez
• The Cochrane Library, http://www.mrw.interscience.
wiley.com/cochrane
• EMBASE, http://www.datastarweb.com/
• BIOSIS, http://www.datastarweb.com/

Table 1 Evidence base included in the review
Category

Number of records
Full papers

Abstracts

Initial search

20

6

  Records excluded

14

2

  Records included

6

4

Level 1 clinical evidence
(systematic review, meta-analysis)

0

0

Level 2 clinical evidence (RCT)

6

4

   Trials other than RCT

0

0

Level 3 clinical evidence
   Case studies

0

0

Economic evidence

0

0

Total records included

6

4

Abbreviation: RCT, randomized controlled trials.
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• National Institute for Health and Clinical Evidence
(NICE), http://www.nice.org.uk/
• York University Centre for Reviews and Dissemination
databases, http://www.crd.york.ac.uk/crdweb

Disease overview
Major depressive disorder (MDD) is diagnosed based on the
presence of a constellation of signs and symptoms that are
characteristic of the illness. This type of phenomenological
definition differs significantly from etiological diagnoses
in which a disease is diagnosed by the presence of a
causative agent (ie, mycobacteria in tuberculosis) or specific
pathophysiological abnormality (ie, plaques and tangles
in Alzheimer’s disease). Nevertheless, using standardized
criteria, the reliability of the diagnosis of major depressive
disorder is high.1 Like most psychiatric disorders, the etiology
and pathophysiology of major depressive disorder is not
well understood, however, we do know that it is highly
prevalent, is often disabling, and responds to both somatic
and psychotherapeutic treatment.
The essential feature of a major depressive episode is
a period of at least two weeks during which there is either
depressed mood or the loss of interest or pleasure in nearly
all activities.2 In children and adolescents, the mood may be
irritable rather than sad. The individual must also experience
at least four additional symptoms drawn from a list that
includes changes in appetite, weight, sleep, or psychomotor
activity; decreased energy; feelings of worthlessness or
guilt; difficulty thinking, concentrating, or making decisions;
and recurrent thoughts of death, suicidal ideation, plans,
or attempts. A symptom must either be newly present or
must have clearly worsened compared with the individual’s
pre-episode status.
The symptoms must persist for most of the day, nearly
every day, for at least two consecutive weeks. The episode
must be accompanied by clinically significant distress or
impairment in social, occupational, or other important areas
of functioning. Diagnostic criteria are listed in Table 2.
For some individuals with milder episodes, functioning
may appear to be normal but requires markedly increased
effort. The mood in a major depressive episode is often
described by the person as depressed, sad, hopeless,
discouraged, or “down in the dumps”. In some cases, sadness
may be denied at first, but may subsequently be elicited by
interview (eg, by pointing out that the individual looks as if he
or she is about to cry). Some individuals complain of feeling
“flat”, having no feelings, or feeling anxious. At times, the
presence of a depressed mood can be inferred from the
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Table 2 Diagnostic criteria for major depressive disorder. Copyright © 1994. American Psychiatric Association. Diagnostic and statistical
manual of mental disorders. 4th edition. Washington, DC: American Psychiatric Association, 1994
Presence of five out of the following symptoms, including depressed mood:
Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad or empty) or observation made by others
(eg, appears tearful). (In children and adolescents, this may be characterized as an irritable mood).
Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day.
Significant weight loss when not dieting or weight gain (eg, a change of more than 5 kg of body weight in a month), or decrease or increase in appetite
nearly every day.
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Insomnia or hypersomnia nearly every day.
Psychomotor agitation or retardation nearly every day.
Fatigue or loss of energy nearly every day.
Feelings of worthlessness or excessive or inappropriate guilt nearly every day.
Diminished ability to think or concentrate, or indecisiveness, nearly every day.
Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for
committing suicide.

person’s facial expression and demeanor. Some patients
emphasize somatic complaints (eg, bodily aches and pains)
rather than reporting feelings of sadness. Many individuals
report or exhibit increased irritability (eg, persistent anger,
a tendency to respond to events with angry outbursts or
blaming others, or an exaggerated sense of frustration over
minor matters).

Epidemiology
MDD is a leading cause of disability due to its high prevalence
and the severity of functional impairment associated with its
symptoms.3 Estimates of the general population prevalence
of mental disorders in the United States have been most
extensively measured using structured lay interviews. The
first such instrument was the Diagnostic Interview Schedule,4
which was developed for use in the Epidemiologic Catchment
Area (ECA) study.5 Using the Diagnostic and Statistical
Manual of Mental Disorders, Third Edition (DSM-III)
criteria,6 MDD prevalence estimates in the ECA sites were
3.0% to 5.9% for lifetime and 1.7% to 3.4% for 12-month
estimates.7
A decade later a second nationally representative survey
using a method similar to the ECA was carried out called
the National Comorbidity Survey (NCS).8 Unlike the ECA,
the NCS used memory priming strategies and respondent
motivation techniques which resulted in prevalence estimates
that were substantially higher: 14.9% for lifetime and 8.6%
for 12-month estimates.9
Since the NCS was conducted there has been an increasing
awareness of depression. A number of large national
programs to promote knowledge about depression have
been launched,10,11 and there has been a large increase in the
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number of Americans who take antidepressant medications.12
Some believed that depression was being overdiagnosed,
and that the prevalence of MDD had been overestimated in
the ECA and NCS studies because of the possibility that a
substantial proportion of respondents classified as cases had
clinically insignificant manifestations of the disease despite
meeting the symptom criteria.13 This concern, that depression
was being overdiagnosed, led to changes in the diagnostic
criteria in the fourth edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV). Symptoms used
to make the diagnosis were required to cause clinically
significant distress or impairment in social, occupational, or
some other important area of functioning.2
The National Comorbidity Survey Replication (NCS-R),
a new national survey of mental disorders, was conducted in
2001–2002, in which DSM-IV criteria were used, including
the requirement of clinical significance.14 In this face-to-face
study of 9,000 adults, age 18 years or older, results similar
to the NCS were found. The prevalence of depression for
lifetime was 16.2%, and for 12-month it was 6.6%. Using the
clinical significance classification, the severity of symptoms
was evaluated: 10.4% of the cases were mild, 38.6%
moderate, 38.0% severe, and 12.9% very severe.

Disease burden
The burden of disease can be measured in a number of
different ways. One of the simpler measures is the mortality
associated with the illness. From a clinical standpoint, the
mortality associated with depression is distressingly high. For
example, a meta-analysis of 23 papers from nine countries
found that depressed persons had a suicide risk 20 times that
of the general population.15
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From an epidemiologic point of view however, death is
a relatively rare outcome of depression. In the World Health
Organization estimates of mortality and burden of disease
for 2002, depression, as a specific illness, was not one of the
top 15 causes of global mortality.16 Self-inflicted injuries,
which include suicide from all mental illnesses and all other
causes, ranked 14. The top three were ischemic heart disease,
cerebrovascular disease, and lower respiratory infections.
Another way of measuring the burden of a disease is by
measuring the disability that it causes. Conditions that are the
chief causes of disability are generally very different from
leading causes of death, and have been mostly ignored in
debates about public health priorities. Because depression
does not kill those who suffer from it, and because it is a
chronic illness with serious symptoms, the burden, as measured by years of life lived with a disability (YLD), is high.
The Global Burden of Disease Study17 found that unipolar
major depression was the leading cause of worldwide YLD
in 1990, accounting for 10.7% of the total.18 The second
leading cause, iron-deficiency anemia, was responsible for
4.7% of YLD, less than half of that caused by depression.
The authors note that the massive but largely unrecognized
burden of mental illness is clearly evident in this study, with
neuropsychiatric disorders filling five of the top ten causes
of disability. These included unipolar major depression,
alcohol use, bipolar disorder, schizophrenia, and obsessive
compulsive disorder.
Disability adjusted life years (DALYs) is a measurement
that blends mortality and disability in order to provide a
more comprehensive representation of the burden of an
illness.19 DALYs are calculated by starting with years of
life lost due to an illness, eg, mortality. An adjustment is
made for the value of time lived at different ages reflecting
the dependence of the young and the elderly on adults. The
time lived with a disability is made comparable with the
time lost due to premature mortality by assigning a severity
weight between 0 and 1, in which a year with no disability
is weighted 0, and a year lost due to premature mortality is
weighted 1. For example, a Class 1 disability, which has a
weight of 0.096, is represented by limited ability to perform
at least one activity in one of the following areas: recreation,
education, procreation, or occupation. By contrast, a Class 4
disability, which has a weight of 0.6, is represented by limited
ability to perform most activities in all of the following areas:
recreation, education, procreation, and occupation.
In 2002 unipolar depressive disorder ranked fourth as
a leading cause of DALYs globally.16 The top three causes
were perinatal conditions, lower respiratory infections, and
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HIV/AIDS. Projections looking forward to 2030 predict
depression rising to the second leading cause of DALYs,
with HIV/AIDS as the leading cause, and ischemic heart
disease rising to third. Overall, despite the relatively low
mortality associated with depression, it is a serious illness
that is one of the largest contributors to the global burden
of disease.

Current therapy options
Treatment guidelines
The American Psychiatric Association (APA) guideline
for the treatment of MDD provides evidence-based
recommendations for the assessment and treatment of
adults with depression.20 Treatment may be divided into
four phases corresponding to the natural history of MDD:
acute, continuation, maintenance, and discontinuation.
The goal during the acute phase is remission of symptoms.
Other phases are centered on maintenance of gains and the
prevention of relapse.
The guidelines extensively discuss the use of antidepressant
medication in the treatment of MDD, but also note that in
addition to pharmacotherapy, psychiatric management should
incorporate a broad array of interventions that include a
diagnostic evaluation, an evaluation of the safety of the
patient and others, an evaluation of the level of functional
impairment, determination of the best treatment setting,
establishing and maintaining a therapeutic alliance, providing
education to patients and families, enhancing treatment
adherence, and working with patients to address early signs
of relapse.
The selection of a medication is influenced by a number
of factors including the nature and severity of a patient’s
symptoms, as well as the patient’s preference. Antidepressant
medications that have been shown to be effective are
listed in Table 3. The guidelines conclude that the overall
effectiveness of antidepressant medications is comparable
between classes and within classes of medications. Therefore,
the initial selection of an antidepressant should be based on
past response, family history of response, anticipated side
effects, and cost. Implementation of pharmacotherapy may
require titration from a low starting dose to the full therapeutic dose at a rate dependent on patient tolerability and
co-morbid medical conditions. Patients who have started an
antidepressant need to be closely monitored for worsening
of symptoms and any adverse effects which may arise.
The APA guidelines provide a broad discussion of
interventions that are considered to be well-supported by
clinical evidence. More specific treatment guidance can
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Table 3 FDA-approved medications for the treatment of major depressive disorder
Starting dose (mg/day)

Target daily dose (mg/day)

citalopram (Celexa®)

20

20–60

fluoxetine (Prozac®)

20

20–60

paroxetine (Paxil , Paxil CR , Pexeva )

20

20–60

sertraline (Zoloft®)

50

50–200

10

10–30

amitriptyline (Elavil®, Endep®)

25–50

100–300

clomipramine (Anafranil )

25

100–250

doxepin (Adapin®, Sinequan®)

25–50

100–300

imipramine (Tofranil®)

25–50

100–300

trimipramine (Surmontil )

25–50

100–300

desipramine (Norpramin®)

25–50

100–300

nortriptyline (Pamelor , Aventyl )

25

50–200

protriptyline (Vivactil®)

10

15–60

amoxapine (Asendin®)

50

100–400

maprotiline (Ludiomil )

50

100–225

150

150–300

 Bupropion, sustained release
(Wellbutrin SR®, Budeprion SR®)

150

150–300

 bupropion extended release
(Wellbutrin XL®, Budeprion XL®)

150

150–300

duloxetine (Cymbalta®)

30

60

venlafaxine XR (Effexor XR®)

37.5

75–225

desvenlafaxine ER (Pristiq )

50

50–100

nefazadone (Serzone®)

50

150–300

trazadone (Desyrel®)

50

50–300

15

45

tranylcypromine (Parnate®)

10

30–60

phenelzine (Nardil®)

15

15–90

selegeline transdermal (Emsam®)

6

9–12

isocarboxazid (Marplan )

20

40–60

SSRIs

®

®

®

escitalopram (Lexapro )
®
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Tricyclics and tertracyclics
®

®

®

®

®

Dopamine–norepinephrine
reuptake inhibitors
Bupropion (Wellbutrin®)

Serotonin–norepinephrine
reuptake inhibitors

®

Serotonin modulators

Norepinephrine–serotonin modulators
mirtazapine (Remeron®)
Monoamine oxidase inhibitors

®

Abbreviations: CR, controlled release; FDA, US Food and Drug Administration; SSRIs, selective serotonin reuptake inhibitors; XR, extended release.

be obtained from the Texas Medication Algorithm Project
(TMAP), which provides step-by-step recommendations for
medication selection. An evaluation of the performance of
the algorithm demonstrated superior outcomes compared
to treatment as usual for patents with moderate to severe
depression.21
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TMAP treatment consists of a total of seven stages for
nonpsychotic MDD and five for psychotic MDD. Each stage
represents management of increasing levels of treatment
resistance. For nonpsychotic MDD, Stage 1 involves monotherapy
that can include a selective serotonin re-uptake inhibitor (SSRI),
bupropion extended release (ER), nefazodone, a serotonin
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norepinephrine reuptake inhibitor (SNRI), or mirtazapine.
DVS was not included in the algorithm because it had not been
released at the time the algorithm was developed.
Partial response at any stage leads to a recommendation
of augmentation. Medications shown to be efficacious when
used to augment antidepressant treatment include lithium,
thyroid hormone, buspirone, and bupropion. In the absence
of a response, or failure of an augmentation strategy, a switch
is recommended to either an antidepressant in the same class
or in a different class (Stage 2). It is also acceptable to switch
immediately to another antidepressant in the same or different
class after partial response with initial monotherapy.
Stage 3 involves the use of an older generation
antidepressant, either a tricyclic antidepressant (TCA) or a
monoamine oxidase inhibitor (MAOI). Because tricyclic
antidepressants can be lethal in overdose,22 and the safe use of
MAOIs involves adherence to a low-tyramine diet,23 these two
classes are usually not used as first line agents. If either a TCA
or MAOI is ineffective in bringing about remission, lithium
augmentation is recommended (Stage 4) if it has not been tried
previously. Stage 5 involves combinations of antidepressants,
and Stage 6 is electroconvulsive therapy (ECT). If ECT is
ineffective or contraindicated, use of medications which have
not been approved for use in the treatment of MDD can be tried
(Stage 7). These include, but are not limited to lamotrigine,
fluvoxamine, and olanzapine.
Psychotic major depression (PMD) is a subtype of MDD
that is defined by the presence of delusions or hallucinations
occurring in the context of a severe depressive episode
(DSM-IV). PMD is associated with greater illness severity,
impairment, comorbidity, and mortality when compared
with MDD. Furthermore, PMD patients tend to have higher
rates of illness chronicity, relapse, and hospitalization.
Typically these patients require adjunctive treatment with
antipsychotic medication or ECT.24 According to the
Texas Medication Algorithm, the first line of treatment for
depression with psychotic features includes a combination of
an antidepressant with an antipsychotic medication (Stage 1).
If only a partial response is achieved a TCA should be tried
(or a non-TCA antidepressant if a TCA was used in Stage 1).
If remission is still not achieved, ECT is indicated, where
appropriate. If this is unsuccessful, lithium augmentation
should be tried, and finally combinations of more than one
antidepressant with an antipsychotic medication.

Comparator drugs
Before 1980, antidepressant treatment consisted primarily of
the TCAs and the MAOIs, both of which affect the activity
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of multiple monoamine neurotransmitters. These medications
also interacted with a number of unrelated receptors which led
to a substantial burden of side effects. The TCAs antagonize
muscarinic cholinergic, H1-histaminic, and alpha-adrenergic
receptors, causing constipation, urinary retention, dry mouth,
sedation, weight gain, and postural hypotension. In addition
to these side effects, the monoamine oxidase inhibitors have
the added risk of potentially severe hypertensive crises due
to the effects of dietary tyramine, which requires dietary
restrictions.25
The introduction of the SSRIs marked the beginning of an
era of greater selectivity. This class of medication includes
fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram,
and escitalopram. Binding almost exclusively to the serotonin
transporter, these new antidepressants avoided many of
the side effects commonly associated with the TCAs and
MAOIs. Initially, it was not clear whether activity at a single
monoamine transporter affected the efficacy of this class of
medication, especially for the treatment of more severely ill
patients. A meta-analysis that included 55 double-blind studies
which compared an SSRI to nonselective agents (primarily
tricyclics), found that SSRIs were slightly less effective than
TCAs when given to inpatients, but in general, the two classes
were approximately equal.26 A later meta-analysis also found
that TCAs had greater efficacy with inpatients, and also
confirmed the superior tolerability of SSRIs.27
Bupropion was introduced around the time of the SSRIs.
Bupropion is unique, being the only antidepressant which
selectively interacts with the norepinephrine and dopamine
systems. Bupropion has not been extensively compared to
TCAs. A number of small studies have found bupropion to
be effective in patients who failed to respond to, or were
unable to tolerate a TCA.28,29 The most widely cited study
which compared bupropion to a TCA found that the TCA
desipramine caused more treatment-emergent mood elevation
in depressed bipolar patients when added to an ongoing
therapeutic regimen of lithium or an anticonvulsant.
Venlafaxine was the first serotonin norepinephrine
reuptake inhibitor (SNRI). Like many of the tricyclics,
venlafaxine binds to the transporter protein of both
norepinephrine and serotonin. Like the SSRIs, venlafaxine
avoids side effects associated with antagonism of muscarinic
cholinergic, H1-histaminic, and alpha-adrenergic receptors.
More recently, duloxetine was introduced, which like
venlafaxine and DVS is a SNRI.
Other antidepressants that interact with multiple
monoamine systems include nefazodone, which is a weaker
serotonin and norepinephrine reuptake inhibitor, but is a
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potent serotonin 5-HT2 receptor antagonist. Nefazodone is
rarely used currently due to the small possibility of hepatic
injury, which could lead to the need for a liver transplant,
or even death.30 Mirtazapine is a potent antagonist of central
alpha-adrenergic autoreceptors, and heteroreceptors and is an
antagonist of serotonin 5-HT2 and 5-HT3 receptors.
A comparison of the efficacy of the SSRIs and the newer
dual-reuptake inhibitors is discussed in detail below in the
context of evaluating the appropriate place in therapy of DVS.

New indications: pain
Antidepressants have received attention for the treatment
of pain because it is believed that norepinephrine plays
an important role in neuropathic pain. Neuropathic pain
is non-nociceptive, therefore response to traditional analgesics
such as opioids and nonsteroidal anti-inflammatory drugs is
substantially reduced.31 TCAs, which like SNRIs block the
reuptake of serotonin and norepinephrine, are considered
first-line agents for most types of neuropathic pain.32 These
agents work in both depressed and nondepressed patients,
and the doses required for neuropathic pain are much smaller
than antidepressant doses. Effects are often seen within a
few days, as opposed to weeks needed for an antidepressant
response.
It is thought that sensitization of neurons in the dorsal
horn of the spinal cord can lead to chronic pain. Increased
spontaneous activity of the dorsal horn neurons, a decreased
threshold, and an increased responsivity to afferent input
can cause hyperalgesia (increased sensitivity to pain)
and allodynia (a painful response to a usually nonpainful
stimulus). Inhibition of the reuptake of serotonin and
norepinephrine within the dorsal horn appears to be the
mechanism by which TCAs exert their analgesic effect.
Unfortunately, the adverse effect profile makes this class
of drugs less than ideal, and the newer, better tolerated SNRIs
are being studied for the treatment of pain. Duloxetine, for
example, has been approved for the treatment of diabetic
neuropathy and fibromyalgia. Venlafaxine, the precursor
molecule of DVS, has been found to be effective at treating a
number of painful conditions including pain associated with
MDD,33 and a number of different neuropathic conditions.32
A randomized study consisting of 40 patients with painful
polyneuropathy found venlafaxine to be as effective as
imipramine.34
Not all studies have supported the efficacy of SNRIs in the
treatment of painful conditions. A recent meta-analysis of eight
trials involving the SSRI paroxetine and the SNRI duloxetine
failed to find an advantage for the dual action antidepressant.35
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Overall, both drugs were superior to placebo but the difference
was small, of uncertain clinical significance, and may have been
due to nonspecific effects related to improvement in mood.
DVS is also being studied for the treatment of pain. A pain
scale was included as part of the large multicenter trials that
established the efficacy of DVS in MDD. The scale used was
the Visual Analog Scale – Pain Intensity (VAS-PI).36 The
VAS-PI is a straight line, 100 mm in length, with the left end
of the line representing no pain and the right end of the line
representing the worst pain. Patients are asked to mark on
the line where they think their pain is. The VAS-PI score is
determined by measuring in millimeters from the left hand end
of the line to the point that the patient marks. The assessment is
highly subjective, and this scale is of most value when looking
at change within individuals, and is of less value for comparing
across a group of individuals at one time point.
Four randomized, double-blind, placebo-controlled trials
found significantly greater decreases in the VAS-PI overall
scores among subjects taking DVS compared to those taking
placebo,9,14,37,38 and in a pooled analysis of two additional
studies.39 Phase II/III studies are currently evaluating DVS
in patients with fibromyalgia.
Although pain in not one of the criteria used by DSM-IV to
establish a diagnosis of MDD, it is commonly experienced by
depressed patients, and plays an important role in the functional
impairment brought on by this disease. A cross-sectional study
of data from a US national household survey conducted in
1997–1998 identified 1,486 adults who met criteria for MDD
or dysthymia.40 Chronic pain such as back pain, chronic
headache, self-reported arthritis, or unspecified chronic pain
was reported by 63% of this sample.
Depressed individuals in this study with comorbid pain
reported more severe psychiatric distress than depressed
persons who did not have pain, and had approximately 20%
more visits to medical providers. Unfortunately, despite the
increased medical utilization, the patients with comorbid pain
were less likely to see a mental health specialist compared
to patients without pain.
Individuals with pain, depression, or both who were
enrolled in the Health and Retirement Study were evaluated
to determine the impact on functioning of pain with unclear
pathology. New onset of limitations in activities of daily
living and work disability were seen with greater frequency
among those who suffered from comorbid pain and depression
compared to those with depression alone. Individuals who
experienced depression plus pain were three to four times
more likely to experience a new limitation in activities of
daily living compared to those with depression alone.
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As the field of psychiatry moves from a primary focus on
symptoms to a broader view of the patient which includes
measures of functioning and quality of life, attention to
pain syndromes associated with depression may become
increasingly important.
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Unmet needs
Despite the variety of treatment options, helping patients
achieve full remission remains challenging. In the largest
naturalistic study of depression, the Sequenced Treatment
Alternatives to Relieve Depression (STAR*D) project, only
about one-third of the participants reached remission after
receiving the first level of treatment, which was citalopram
as monotherapy.41 Those who did not become symptom-free
were advanced to additional levels, however, remission rates
were progressively lower in each subsequent treatment level:
25% in level 2, and for those who did not achieve remission
in level 2, 12% to 20% in level 3, and 10% in level 4. Over
the course of all four treatment levels, almost 70% of those
who did not withdraw from the study became symptom-free.
However, the rate at which participants withdrew from the
trial rose with each level: 21% withdrew after level 1, 30%
after level 2, and 42% after level 3.
STAR*D used remission as an outcome measure, meaning
that patients had to be essentially symptom-free. If response
is used as an outcome measure, the success rate tends to be
approximately 60%–70%. Response indicates that a patient
has experienced a reduction in symptoms, and response is
formally defined as a reduction in a depression rating scale
score of at least 50%. One of the drawbacks of using response
as a measure of success, however, is that residual symptoms
of depression can cause substantial morbidity, and their
presence is associated with a high risk of relapse.42
Tolerability can also be a problem with current
antidepressant therapy. All newer antidepressants, with the
exception of bupropion, carry the risk of inducing sexual side
effects, which may, along with other troublesome side effects,
contribute to early discontinuation of treatment.43 Adherence
to medication can be particularly difficult during periods of
normal mood when a medication is being used to prevent
future episodes. Tolerability becomes increasingly important
as the duration of medication use increases.
Another unmet need is for rapid onset of action.
While some improvement is possible early in treatment,
it generally takes weeks for an antidepressant to have its
full effect.44 The reason for this delay is unknown. Although
antidepressants cause an immediate increase in the activity
of monoamine neurotransmitters, it is believed that chronic
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drug administration drives the production of adaptations in
postreceptor signaling pathways, including regulation of
neuronal gene expression, which is ultimately responsible
for the therapeutic effects.45 A medication that bypassed the
monoamine system, and directly targeted these downstream
effects would be likely to have a more rapid onset of action.
In general, currently available antidepressants are
effective medications. Nevertheless, there remains the need
for new medications with higher remission rates, better
tolerability, and a more rapid onset of action. Rather than
being a revolutionary drug, DVS more modestly advances our
ability to treat depression. DVS expands the limited options
available to clinicians to target more than one neurotransmitter, and it does it in a way that avoids interaction with
post-synaptic receptors associated with the high side-effect
burden of the previous generation of antidepressants.

Clinical evidence with desvenlafaxine
DVS was studied in phase II and III randomized placebocontrolled trials that supported the US FDA indication for
MDD.37–39,46–48 Phase II studies, although positive, were not
published.
The first phase III study was an eight-week double-blind,
placebo-controlled trial that included 480 adult outpatients
with MDD. The change from baseline to endpoint in
the 17-item Hamilton Rating Scale for Depression
(HAM-D17) was used as the primary outcome measure 37
(Table 4). Subjects were recruited from 25 centers throughout
the United States. Secondary efficacy measures used were
the Clinical Global Impressions-Improvement scale (CGI-I),
Montgomery-Asberg Depression Rating Scale (MADRS),
Clinical Global Impressions-Severity of Illness scale
(CGI-S), rates of response (50% decrease of Ham-D17
from baseline) and remission (HAMD-D17 score 7), and
the VAS-PI overall score. Patients were randomly assigned
at baseline to one of three fixed doses of DVS (100, 200,
or 400 mg per day) or placebo. All patients who completed
the study, regardless of treatment group, had the option of
enrolling in a long-term, open-label extension study.
After eight weeks of treatment, the mean HAM-D17
scores for DVS 100 mg per day (12.75) and 400 mg per day
(12.50) were significantly lower than for placebo (15.31;
p = 0.0038 and p = 0.0023, respectively); for DVS 200 mg
per day, the mean score was 13.31 (p = 0.0764). CGI-I and
MADRS results were significant for all groups; CGI-S results
were significant with 100 mg per day and 400 mg per day.
Response rates were significantly greater for DVS 100 mg per
day (51%) and 400 mg per day (48%) versus placebo (35%;

Core Evidence 2009:4

Dovepress

Desvenlafaxine in major depressive disorder

Table 4 Desvenlafaxine compared to placebo and venlafaxine: adjusted mean change in HAMD17 from baseline in six 8-week randomized
controlled trials
Level of evidence

Once daily drug
dose (mg) (n)

Adjusted mean
change from baseline

p-value vs
placebo

Reference

2

DVS 100 (114)

-10.60

p = 0.0038

Demartinis et al37

DVS 200 (116)

-9.63

p = 0.0764
p = 0.0023
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2

2
2

2

2

DVS 400 (113)

-10.74

Placebo (118)

-7.65

DVS 200 (121)

-12.6

p = 0.002

DVS 400 (124)

-12.1

p = 0.008

Placebo (124)

-9.3

DVS 100–200 (120)

-9.6

Placebo (114)

-8.6

DVS 50 (158)

Septien-Velez et al38

p = 0.277

Liebowitz et al48

-11.5

p = 0.018

Liebowitz et al47

DVS 100 (157)

-11.0

p = 0.065

Placebo (159)

-9.5

DVS 50 (145)

-14.4

p  0.001

DVS 100 (126)

-14.9

p  0.001

Placebo (138)

-11.5

DVS 200–400 (226)

-14.21

p  0.001

VEN ER 75–150 (127)

-14.26

p = 0.001

VEN ER 150–225 (115)

-14.56

p  0.001

Placebo (245)

-11.87

Boyer et al46

Lieberman et al39
(pooled analysis)

Abbreviations: DVS, desvenlafaxine; VEN ER, venlafaxine ER.

p = 0.017 and p = 0.046, respectively); the response rate for
DVS 200 mg per day was 45% (p = 0.142). Remission rates
were significantly greater for DVS 400 mg per day (32%)
versus placebo (19%; p = 0.035); remission rates were 30%
for DVS 100 mg per day (p = 0.093) and 28% for DVS
200 mg per day (p = 0.126).
Treatment with DVS was associated with improvement in
some painful symptoms at the 100 mg dose, but for overall
pain scores, neither the 200 mg nor the 400 mg dose group
was statistically different from placebo. Greater attrition at
higher doses early in the study may have made it difficult to
measure dose response effects. Furthermore, most patients
did not have a high level of pain at baseline, as pain was not
an inclusion criterion for this study. Greater benefit may be
observed with greater severity of pain at baseline.
The most commonly reported adverse events were
nausea, insomnia, somnolence, dry mouth, dizziness,
sweating, nervousness, anorexia, constipation, fatigue, and
abnormal ejaculation/orgasm. Nausea occurred at the highest
frequency (35%, 31%, and 41% in the DVS 100 mg, 200 mg,
and 400 mg groups, respectively, compared with 8% in the
placebo group). Among patients who discontinued due to
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adverse events, nausea was the most common adverse event
cited as the reason for discontinuation.
Four patients had serious adverse events, including
one death. One patient in the 100 mg group committed
suicide on study day 5. It is not known whether this patient
had taken any of the medication that was dispensed at the
baseline visit. Three additional participants were reported
to have had serious adverse events. One patient (400 mg)
attempted suicide, another had a dystonic reaction from
taking promethazine, and one patient in the placebo group
experienced chest pain.
Mean increases in blood pressure in the DVS groups
were statistically significant when compared with baseline
and placebo at all weeks and the final on-therapy evaluation.
None of the changes in vital signs were deemed to be of
clinical significance. All DVS dosage groups had statistically
significant decreases in weight when compared with baseline
and placebo. One patient had clinically significant weight
loss of greater than 7% of baseline body weight.
Statistically significant increases from baseline to end
point were observed for the following laboratory values:
alanine aminotransferase (ALT), aspartate aminotransferase
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(AST), gamma-glutamyl transferase (GGT), bilirubin
alkaline phosphatase, fasting total cholesterol, and fasting
triglycerides. In general, these changes were not clinically
significant. Only four DVS-treated patients were determined
to have clinically significant laboratory abnormalities.
Statistically significant increases from baseline in mean
heart rate was observed for all DVS treatment groups
when compared to placebo. Several small but statistically
significant changes in electrocardiogram (ECG) intervals
were observed, most of which were attributable to increases
in heart rate (shortening of PR and QRS intervals).
Overall, in the first phase III study, DVS was found to
have efficacy comparable to other antidepressant medications.
Treatment with DVS was generally well tolerated, particularly
at the 100 mg dose, with an adverse effect profile similar to
other SNRIs. The rates of response (45%–51%) and remission
(28%–32%) were consistent with those observed in other
trials of short-term antidepressant treatment.49
The absence of a statistically significant difference
between DVS 200 mg and placebo on the primary outcome
measure is curious in light of the significant differences seen
with the 100 mg and 400 mg doses. Considering that approximately half of clinical trials of antidepressants that ultimately
receive approval fail to show a significant difference between
active drug and placebo,50 this finding may be related to type II
error rather than true lack of efficacy. Lack of separation
seems to be particularly likely in fixed dose studies. In support
of this interpretation, the DVS 200 mg group demonstrated
statistically significant differences from placebo on the key
secondary outcome measures (CGI-I, MADRS) as well as
on measures of overall functioning.
A similar eight-week phase III randomized, double-blind,
parallel group, placebo-controlled multicenter trial conducted
in Europe (30 centers) and South Africa (5 centers) evaluated
the 200 mg and 400 mg doses.38 As with the first study, the
primary efficacy measure was change from baseline on the
HAM-D17. Similar secondary measures were used as well.
At the final on-therapy evaluation, adjusted mean change from
baseline in the HAM-D17 total score was significantly greater
with both DVS 200 mg per day (-12.6 ± 0.75; p = 0.002) and
DVS 400 mg per day (-12.1 ± 0.74; p = 0.008), compared
with placebo (-9.3 ± 0.74). A significant difference in total
score vs. placebo was observed starting at week 4 for both
DVS 200 mg per day (p  0.004) and DVS 400 mg per day
(p  0.049), and were sustained until the end of the study.
Both doses of DVS also performed well on the secondary
measures. Response rates were 60%, 56%, and 38%
for DVS 200 mg per day, 400 mg per day and placebo,
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respectively. Significantly more participants treated with
DVS 200 mg per day achieved remission compared with
placebo (37% vs 23%, respectively; p = 0.017). Although
not statistically significant, remission rates on the HAM-D17
were numerically higher for DVS 400 mg per day than for
placebo (34% vs 23%, respectively; p = 0.066).
Treatment-emergent adverse events were reported by
70% of placebo participants, 85% of DVS 200 mg per day
participants and 90% of DVS 400 mg per day participants.
The adverse events reported were similar to the first study.
An analysis of change over time found that the side effects
tended to resolve as participants continued to take the
medication. The incidence of the most common treatmentemergent adverse events (nausea, dry mouth, sweating,
dizziness, fatigue, and constipation) was highest during the
first week of treatment and decreased rapidly so that from
week three onward no major differences were observed
between the DVS and placebo treatment groups.
DVS 400 mg per day was associated with small but
significant increases from baseline in mean pulse rate and
diastolic blood pressure; a significant decrease from baseline
in mean body weight was observed for participants in both
DVS groups.
Statistically significant changes were seen in the 400 mg
group in the following laboratory studies: ALT, AST, GGT,
bilirubin, alkaline phosphatase and fasting high-density
lipoprotein (HDL) cholesterol. Only the differences in bilirubin
(decrease) and alkaline phosphatase (increase) were statistically
significant in the 200 mg group. None of the laboratory changes
were associated with clinical symptoms, and all were reversed
when DVS treatment was discontinued.
As seen in the first study, several small but statistically
significant ECG changes were observed in both DVS
treatment groups. As before, these changes were attributable
to increases in mean heart rate, and were not clinically
significant.
The third phase III trial failed to separate from placebo on
the primary outcome measure.48 This study utilized a 100 mg
per day starting dose, with an increase to 200 mg per day at
two weeks. The dose could be decreased back to 100 mg for
safety or tolerability reasons. It was an eight-week multicenter
double-blind randomized trial involving 247 outpatients, and
used the same primary and secondary efficacy measures as
the two previous trials. Following the initial titration period
(days 1–14) the mean daily dose of DVS for the intent-to-treat
population was 179.0 to 195.3 mg. For those who completed
the entire eight-week trial, the mean daily dose was 182.4
to 195.2 mg.
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At this point the weight of evidence supported the
efficacy and safety of DVS, and substantial advantages of
higher doses over lower doses had not been seen. The next
study that was undertaken attempted to better establish the
minimum effective dose in a three arm study consisting of
DVS 100 mg, DVS 50 mg, and placebo.47 This multi-center,
double-blind study enrolled 447 outpatients who were treated
for eight weeks. The inclusion and exclusion criteria, and
primary and secondary efficacy measures were the same as
in the previous trials.
DVS 50 mg per day was associated with a significantly
greater mean change from baseline on the HAM-D17
(-11.5) compared to placebo (-9.5; p = 0.018); the 100 mg
dose group (-11.0) did not achieve statistical significance
(p = 0.065). The 100 mg group did, however, demonstrate
significant improvements compared with placebo on several
secondary efficacy measures, including the 6-item Hamilton
Depression Rating Scale and the VAS-PI total score.
An important addition to this study was the inclusion
of the Discontinuation-Emergent Signs and Symptoms
(DESS) checklist, which was used to evaluate adverse
events that occurred or worsened during and after the
seven-day taper period when the medication was discontinued.
Discontinuation-related symptoms are common with many
antidepressants,51 and may be more common with SNRIs.52
In this study, however, the DESS score for both DVS doses
appeared to be comparable or lower than DESS scores
reported in published studies for other SNRIs and SSRIs.53,54
Additionally, neither the tapered DVS 100 mg per day group,
nor the group discontinued from DVS 50 mg per day without
a taper, had a mean change in DESS score of greater than
three points, the threshold defined as a “discontinuation
syndrome”.54
Both DVS doses were generally well tolerated. Of note,
nausea, which was the most frequently reported adverse
event in previous studies, was not among the most commonly
reported in this study. Moreover, the rate of nausea associated
with DVS during the first week of treatment (at a dose of
50 mg per day) was substantially lower compared with those
in a previous study (22%–31%) in which DVS treatment
was initiated at 100 mg per day.37 Rates of discontinuation
(3%–7%) due to adverse events in this study were also
lower than in the previous studies which used higher doses
(11%–21%). Withdrawals due to adverse events were evenly
distributed throughout the treatment period, whereas previous
studies, in which treatment was initiated at doses of 100 mg
per day or higher, most discontinuation events occurred
during the first two weeks of treatment.
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The lower dose strategy was tested in a similar study of
483 subjects conducted in multiple centers throughout Europe
and South Africa.46 Both doses were superior to placebo
across all primary and secondary efficacy measures. As in
the previous study, the efficacy of the 50 mg and 100 mg
doses was comparable to that observed at higher doses,37,38
and adverse events were similar to those reported with other
SNRIs.55 As expected, fewer adverse events were reported
compared to studies which used higher doses.
The two 50 mg per day studies found this dose to be
effective and well tolerated even without initial titration.
Additionally, this dose was associated with minimal side
effects upon discontinuation without a taper. A question that
arises from these results is whether an even smaller dose
would also be effective. Ideally, dose-finding studies test
progressively lower doses until an inactive dose is identified,
thereby establishing a minimum floor. Thus far 50 mg is the
lowest dose tested in a published study.
Two similarly designed studies compared DVS to
placebo using venlafaxine ER as an active control. Although
individually neither demonstrated statistically significant
differences on the primary outcome measure, a pooled
analysis supported the superiority of DVS compared to
placebo.39 One of the studies was done in the United States,
and the other in Europe. Both had a high placebo response
rate, and in retrospect it appeared that they had not been
adequately powered to detect a difference in the setting
of this high placebo response rate. The similarities of the
protocols allowed the results were to be pooled in order to
increase the number of subjects in the analysis, and provide
adequate statistical power.
A total of 738 patients were randomly assigned to
eight weeks of treatment with placebo (250 patients), DVS
(239 patients), or venlafaxine ER (249 patients). The initial
target dose of DVS was 200 mg per day with the option to
increase to 400 mg per day after study day 28. In the European
study venlafaxine ER was dosed between 75 mg per day and
150 mg per day, while in the US study the allowable range was
75 mg per day to 225 mg per day. Because of this difference in
dosing guidelines, the venlafaxine ER data was not pooled.
The primary outcome measure was change from baseline
in the 17-item Hamilton Rating Scale for Depression
(HAM-D17). A statistically significant difference between
DVS and placebo was observed at week three, and maintained
throughout the treatment period. There were no significant
differences between DVS and venlafaxine ER, however the
study was not designed to identify differences between these
two groups.
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A number of secondary measures were also found to
be statistically significant, including the CGI-S, and the
visual analog scale for back pain, chest pain, arm/leg/joint
pain, and overall pain. Clinical Global Impression Scale –
Improvement (CGI-I) and improvement in stomach pain were
not statistically different from placebo. Adverse effects were
those typically seen in other studies, and included nausea,
somnolence, dry mouth, and sweating.
The high placebo response rate observed in the two studies
reflects the increasing placebo response rate observed in
many studies over recent years. A review of controlled trials
published in English between January 1981 and December
2000 in which adult outpatients with MDD were randomly
assigned to receive medication or placebo found that the
placebo response rate has increased by approximately 7% per
decade.56 Variability was large ranging from approximately
10% to more than 50%. The placebo response rate in the
pooled DVS analysis was 47%.
In summary, desvenlafaxine at the 50 mg dose has been
shown to be superior to placebo in treating MDD. While
doses as high as 400 mg per day have been tested, there is
no evidence that doses higher than 50 mg/day are more
effective. In some studies, higher doses did not separate
from placebo, whereas lower doses did.37,48 The reason for
this difference is unclear. A consistent finding, however, is
the greater incidence of adverse events at higher doses; the
50 mg dose was the best tolerated. All of the phase III studies
using desvenlafaxine for depression have been short term
(eight weeks). Long term placebo-controlled maintenance
data is not yet available.
With respect to safety and tolerability, the most
commonly observed side effects of desvenlafaxine were
nausea, dry mouth, somnolence, sweating, constipation
and decreased appetite, resulting in statistically significant
weight loss ranging from 0.18 to 1.82 kg over the course of
eight weeks.
Cardiovascular side effects were observed which were
small, yet statistically significant. Increases in supine pulse
rate ranged from 0.69 to 5.79 beats per minute. Increases
in systolic blood pressure ranged from 0.61 to 4.05 mmHg.
Mean increases in diastolic blood pressure ranged from
0.66 to 3.41 mmHg. Mean increases in QTc ranged from
0.18 to 7.25 milliseconds. It should be noted that individual
patients may experience larger changes, and while it does not
appear to be necessary to monitor the ECG, blood pressure
should be monitored, as with the other SNRIs.
There were a number of laboratory findings associated with
desvenlafaxine treatment. Statistically significant increases
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were observed in alkaline phosphatase (1.1–8.9 U/L), GGT
(1.3–11.0 U/L), AST (1.6–2.9 U/L), ALT (3.9–4.2 U/L), total
cholesterol (0.10–0.23 mmol/L), HDL (0.035–0.060 mmol/L),
low-density lipoproteins (LDL; 0.05–0.17 mmol/L), and
triglycerides (0.11–0.13 mmol/L). Statistically significant
decreases were observed in total bilirubin ranging
from 0.6 to 2.2 mg/dL. While these test changes were not
associated with clinical findings, laboratory monitoring for
individuals undergoing treatment with desvenlafaxine may
be indicated for individuals with pre-existing liver or lipid
abnormalities.
Although there were no observations of desvenlafaxine
causing suicidality, like all antidepressants, desvenlafaxine
carries the required FDA black box warning on suicidality.
Good clinical practice requires close monitoring of any
patient treated with antidepressants for emerging suicidality,
particularly in severely depressed patients initiating
therapy.

Economic evidence
Due to the high prevalence of MDD, the availability of
effective, well tolerated antidepressants, and the diminishing
stigma of receiving treatment, medical costs associated
with MDD constitute a significant portion of health
care expenditures. The need for information on the cost
effectiveness of interventions for depression is being driven
by rising costs and the scarcity of mental health resources.
Economic evaluations aim to combine costs and patient
outcomes in one analysis. Outcome measures may include
the cost per success (for example remission), cost per
symptom-free day, or total cost, both inpatient and outpatient,
over a specified period of time. Although the focus is often
on the cost of the antidepressant drug itself, in actuality,
drug costs represent only 10% of the overall economic
costs of depression.57 Consequently, other factors, such as
hospitalization, physician costs, and indirect costs associated
with lost productivity must be included in a comprehensive
analysis.
Because DVS was introduced only recently, studies
involving economic analyses have not yet been performed.
Indirect evidence, involving the evaluation of venlafaxine,
the parent compound of DVS, suggests that DVS has the
potential to be a cost-effective option in the treatment of
MDD. Venlafaxine has been compared to both generic SSRIs
and the older tricyclic antidepressants, and in most studies has
been shown to be the more cost effective agent.21,58–63 This is
largely driven by the small, though statistically significant
advantage that the SNRIs have in bringing about response
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and remission which result in savings that outweigh the
higher acquisition costs.64 One study concluded that that the
cost of an SSRI could be reduced to a few pennies per day,
and the cost of a tricyclic to zero before the overall cost of
venlafaxine treatment ceased to be lowest.60
Some studies found escitalopram, which also has higher
acquisition costs than the generic SSRIs, to be more cost
effective than venlafaxine,65–67 although others did not,61,68,69
making this finding less consistent.
The inclusion of the cost of treating medical comorbities
in the analysis appears to be important. Some analyses
found that there was no cost advantage to treatment with
venlafaxine compared to SSRIs until the medical costs of
nonpsychiatric care was included in the analysis.62,63 This
finding may reflect the efficacy of venlafaxine and other
SNRIs in the treatment of pain that is frequently seen in
patients with MDD.
Looking beyond the cost of the antidepressant itself,
agents with a dual mechanism of action are associated
with higher rates of remission, more depression free days,
and reduced pain-symptom morbidity, which can lead to
reduced health service utilization. An important caveat is
that the evidence reviewed involved venlafaxine rather
than DVS. Although DVS has the theoretical advantage of
noradrenergic activity at typical starting doses, whether DVS
will show cost advantages similar to venlafaxine remains
to be seen, particularly in the setting of the availability of
generic venlafaxine.

Dosage and administration
Desvenlafaxine is available as an ER tablet in the form
of desvenlafaxine succinate, a stable salt, which results in
bioavailablility of 80% when taken orally. Each tablet contains
76 mg or 152 mg of desvenlafaxine succinate, equivalent to
50 mg or 100 mg of desvenlafaxine.70 The recommended
starting and maintenance dose of desvenlafaxine is a 50 mg
ER tablet taken orally once daily with or without food. Based
on published data, there is no clinical evidence that doses
greater than 50 mg per day confer any additional benefit for
treatment of MDD,47 and higher doses may be associated with
greater incidence of adverse events, especially nausea.37,38,48
However, some patients may require a higher dose, and
Pristiq® is available in both 50 mg and 100 mg. Doses as high
as 400 mg per day have been shown to be effective. There
is also some evidence that higher doses are more effective
for pain symptoms.38
Because Pristiq® tablets have an ER formulation, the
tablet can not be divided, crushed or chewed; thus titration
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in increments of less than 50 mg has to be done on an every
other day basis. Discontinuation of a 50 mg per day dose
without a taper was not associated with a discontinuation
syndrome,47 however, gradual dose reduction from higher
doses is recommended.

Place in therapy
SNRIs, SSRIs, and the other newer antidepressants are
all considered first line treatments for MDD. No single
antidepressant works best for all patients, and some patients
may need to try numerous medications before they find
one that is both effective and tolerable. Consequently, it is
important to have a broad range of options available.
It is generally believed that all antidepressants approved
by the US FDA are similarly effective.71 However, because
SNRIs block the reuptake of both norepinephrine and
serotonin there has been some interest in whether they may
have greater efficacy than the SSRIs which only block the
reuptake of serotonin. Because DVS has been available
for only a short period of time, head-to-head comparisons
with other SSRIs have not yet been performed. A number
of studies have been published comparing venlafaxine to
SSRIs, however, and these have tended to favor the SNRI,
but only by small margins.
A metaanalysis combined data from 34 studies comparing
venlafaxine to fluoxetine (n = 20), paroxetine (n = 8),
sertraline (n = 3), citalopram (n = 2), and fluvoxamine (n = 1).
The primary outcome measure was remission following eight
weeks of treatment. The differences numerically favored
venlafaxine over SSRIs in 28 studies, with six studies
numerically favoring the SSRI over venlafaxine. Overall,
venlafaxine therapy was associated with a statistically
significant 5.9% (95% confidence interval [CI]: 0.038–0.081)
advantage.72
Tolerability was similar for the two classes of medication.
Overall discontinuation rates for any reason were 28% for the
pooled venlafaxine and 27% for the pooled SSRI treatment
groups. A higher percentage (11%) of venlafaxine-treated
patients discontinued therapy because of adverse events
compared with SSRIs (9%; p = 0.0011). Discontinuation
rates because of lack of efficacy were 4% for venlafaxine
and 5% for SSRIs.
A similar study that looked at response rather than
remission also found a modest advantage for the dual
action agents.73 This metaanalysis, which included 93 trials
with 17,036 subjects, used a broad definition of dual action
antidepressant, which included dual reuptake inhibitors, and
drugs that affected both the serotonin and norepinephrine
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systems in other ways. The specific drugs included were
venlafaxine, duloxetine, milnacipran, mirtazapine, mianserin,
and moclobemide.
The average response rate of the dual action antidepressants
was 63.6% compared to 59.3% for the SSRIs. The number
needed to treat was 24, indicating that 24 patients would
need to be treated with dual-action antidepressant drugs
instead of SSRIs in order to obtain one additional responder.
This number may have underestimated the true comparative
advantage of SNRIs due to the broad inclusion of non-SNRI
medications.
If a patient demonstrates treatment resistance by failing
to respond to a trial of antidepressant therapy, guidance
on selecting the next most appropriate step is sparse.
Unfortunately, failure to respond to an antidepressant is
common. As noted above, in the STAR*D trial, only about
30% of patients were in remission following up to 12 weeks
of therapy with the SSRI citalopram.41
If a patient continues to experience depressive symptoms,
despite an optimal antidepressant trial, two general strategies
exist. The first involves augmentation with a second
medication, and the other involves discontinuing the first
antidepressant, and switching to a second.74 Augmentation
requires a patient to take two medications, while switching
maintains treatment with a single one. The latter, more simple
medication regimen may have advantages with regard to
adherence and minimization of side effects.
For patients who are initially given an SSRI antidepressant,
switch options include a within-class switch to a second
SSRI, or an across-class switch to a medication with a
different mechanism of action. Few studies have been
carried out comparing within class to across class switches.
The largest study was done as part of the STAR*D study
in which patients who did not experience remission after
14 weeks of citalopram were randomized to a second SSRI
(sertraline), bupropion (a medication with norepinephrine
and dopamine activity), or venlafaxine.75 A total of 727
subjects were enrolled in this study, and no statistically
significant differences were found among the three study
arms. Remission rates were: sertraline, 17.6%; bupropion,
21.3%; and venlafaxine, 24.8%.
The STAR*D study was powered to detect a 15%
between-group difference in remission rates. In order to
increase the power of the statistical analysis, and detect
smaller, yet potentially meaningful differences between the
two switch strategies, Papakostas and colleagues performed
a meta-analysis of data from four clinical trials, which
included 1,496 subjects. Subjects in these studies who did not
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experience remission on various SSRIs were randomized to
receive a second SSRI (paroxetine, sertraline, or citalopram)
or a non-SSRI antidepressant (venlafaxine, mirtazapine, or
bupropion). Patients who received an across-class switch
were significantly more likely to experience remission than
those who had a within-class switch (pooled risk ratio for
remission 1.29; p = 0.007). The number needed to treat in
this analysis was 22.
DVS was not available when these comparative studies
were undertaken. Although one may hypothesize that its
performance would be similar to the parent compound
venlafaxine, it remains to be established in clinical trials.
An advantage that DVS may have is that it is more equal
in its effect on serotonin and norepinephrine compared to
venlafaxine. Venlafaxine does not have an appreciable effect
on the norepinephrine system until it is titrated to approximately
225 to 375 mg per day.76 Doses of this magnitude are
frequently used in clinical trials, but doses below 100 mg
are more typical in routine practice.43 Consequently, many
patients receiving venlafaxine in a non-research environment
are essentially experiencing an SSRI effect. Because DVS
blocks the reuptake of both serotonin and norepinephrine at
starting doses, patients in real world settings may experience
dual reuptake inhibition with greater consistency.
Given the brief duration of DVS availability, its ultimate
place in therapy will become more clear over time. As a new
SNRI, it may prove to be a valuable addition to available
antidepressant medications. The clinical superiority of the
dual action antidepressants over many of the SSRIs is a well
replicated finding, but the effect size is small. Perhaps more
important is the potential for economic advantages over
older agents, and efficacy in the treatment of pain. Comorbid
pain appears to be common among patients suffering from
depression, but despite the serious functional impairment
it can cause, it has received little attention until recently.
Like duloxetine, treatment with DVS was associated with
statistically significant reductions in most pain scales that
were used in the registrational trials. SSRIs have not been
found to be particularly effective in treating pain, but
additional head-to-head comparisons between SSRIs and
SNRIs are needed before firm conclusions can be drawn.
Among the newer antidepressants, only duloxetine and
DVS block the reuptake of both serotonin and norepinephrine
at starting doses. Because only a minority of patients
experience remission after an initial trial of an antidepressant,
and because it is not possible to know in advance which
antidepressant will help a particular patient, a greater number
of options can lead to better results. As one of only a limited
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number of SNRIs, DVS has the potential to play a significant
role in improving treatment outcomes.
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